This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Boston Scientific (BSX) mCRM System Study Outcome Favorable
by Zacks Equity Research
Boston Scientific (BSX) mCRM System is designed to communicate wirelessly and coordinate painless intracardiac anti-tachycardia pacing (ATP) therapy.
Medtronic (MDT) Reports Favorable SPHERE Per-AF Trial Outcome
by Zacks Equity Research
Medtronic's (MDT) Affera Mapping and Ablation System with Sphere-9 Catheter achieves endpoints for safety and efficacy for the treatment of AFib.
Haemonetics' (HAE) Hospital & Plasma Segments, Innovation Aid
by Zacks Equity Research
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Maravai (MRVI) Advances in RNA Research With New Collaboration
by Zacks Equity Research
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
Haemonetics (HAE) Stock Up 10.9% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.
Tandem Diabetes (TNDM) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Tandem Diabetes (TNDM) outperforms the industry, owing to its impressive series of product launches and an impressive quarterly performance.
4 Best Momentum Stocks Worth a Buy Using Driehaus Strategy
by Tirthankar Chakraborty
Stocks like Wingstop (WING), Medpace (MEDP), Comfort Systems USA (FIX) and HCI Group (HCI) have been selected as the momentum picks for the day using the Driehaus strategy.
Butterfly Network (BFLY) Unveils iQ+ Bladder Ultrasound Scanner
by Zacks Equity Research
Butterfly Network (BFLY) uses proprietary Ultrasound-on-Chip technology to streamline the bladder scanning process.
Align Technology (ALGN) Gains From Innovation, Global Expansion
by Zacks Equity Research
In the United States, Align Technology (ALGN) is focused on reaching young adults as well as teens and their parents through famous athletes, influencers and fashion designers.
Prestige Consumer (PBH) Q4 Earnings Miss, Operating Margin Falls
by Zacks Equity Research
Prestige Consumer's (PBH) Q4 business suffers from supply chain pressure that impacts its ability to fulfill retailer orders.
Labcorp (LH) to Assess Preeclampsia Risk With New Test
by Zacks Equity Research
Labcorp's (LH) new first-trimester test is the latest addition to its dedication to improving women's health.
Profound Medical (PROF) Adds AI to Prostate Cancer Treatment
by Zacks Equity Research
Profound Medical's (PROF) Contouring Assistant integrates AI into prostate cancer procedures, thereby streamlining the treatment planning process and enhancing both efficiency and precision.
Thermo Fisher (TMO) Unveils New Extended Blood Genotyping Array
by Zacks Equity Research
Thermo Fisher's (TMO) new Applied Biosystems Axiom BloodGenomiX Array and Software provide a high-throughput solution for more precise blood matching research.
Here's Why Investors Should Retain QIAGEN (QGEN) Stock Now
by Zacks Equity Research
QIAGEN's (QGEN) solid potential in the NGS platform buoys optimism for investors.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC), owing to strategic acquisitions and potential in Henry Schein One.
Centene (CNC) to Continue Serving Kansas' Medicaid Members
by Zacks Equity Research
Centene's (CNC) subsidiary wins contract from the Kansas Department of Administration to continue providing comprehensive healthcare services to the KanCare program's members.
Here's Why You Should Buy Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN) led by expansion in new geographies and upbeat guidance.
QIAGEN's (QGEN) QCI Interpret Gets European IVDR Certification
by Zacks Equity Research
QIAGEN's (QGEN) Clinical Insight Interpret is the first NGS interpretation platform approved by IVDR for use in cancer and hereditary applications.
Here's Why You Should Retain Zimmer Biomet (ZBH) Stock for Now
by Zacks Equity Research
Strong procedure recovery and progress on the four-pillar strategy bode well for Zimmer Biomet (ZBH).
Senseonics' (SENS) Deal With Mercy to Drive Eversense CGM Sales
by Zacks Equity Research
Senseonics Holdings (SENS) collaborates with Mercy to bring its Eversense CGM to a healthcare system that is likely to drive its adoption.
Stereotaxis (STXS) Inks Deal to Buy Access Point Technologies
by Zacks Equity Research
Stereotaxis' (STXS) deal to acquire electrophysiology catheter developer, Access Point Technologies, is likely to strengthen its position within the catheter market.
Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSMD
Alcon (ALC) Q1 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
Alcon's (ALC) Q1 results reflect substantial growth in its franchises on the back of healthy markets.
Reasons to Add The Cooper Companies (COO) to Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.
Zacks.com featured highlights Medpace, American Axle, Diebold Nixdorf, Euronet and Omnicom
by Zacks Equity Research
Medpace, American Axle, Diebold Nixdorf, Euronet and Omnicom have been highlighted in this Screen of The Week article.